Loading...

NBIX NEUROCRINE BIOSCIENCES INC Product Launches 8-K Filing

NRCR

NBX

NEUROCRINE BIOSCIENCES INC

(NBIX)

2024 8-K

Show Summary

Show Summary

Appointing of Directors

Financial Statements

Management Change

Financial Results

License Agreement Update

Share Repurchase

Q3 Earnings Report

Leadership Transition

Positive Study Results

Financial Results for Q2 2024

Management Change

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Agreement with Zydus

Patent Litigation Settlement

Financial Results Announcement

Settlement of Patent Litiga...

Announcement of Study Results

Phase 3 Study Results

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

External Links:

Neurocrine Biosciences announced positive results from a Phase 2 study of its schizophrenia treatment NBI-1117568, showing a significant reduction in symptoms and plans to advance to Phase 3 in early 2025.

AI Assistant

NEUROCRINE BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.